Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06020287
Other study ID # NanjingUSM202388
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 1, 2020
Est. completion date December 27, 2022

Study information

Verified date August 2023
Source Nanjing University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study was to compare the perioperative outcomes, postoperative urinary control rates and positive surgical margin (PSM) rates of the robot-assisted laparoscopic radical prostatectomy combined anterior and posterior approach (AP-RARP) with the Retzius-sparing approach (RS-RARP) and anterior approach (anterior-RARP) in the treatment of prostate cancer. The main question it aims to answer was: • The early therapeutic efficacy of the robot-assisted laparoscopic radical prostatectomy combined anterior and posterior approach Participants has been underwent: - AP-RARP - RS-RARP - anterior-RARP Researchers compared the three groups to see if AP-RARP combines the advantages of anterior and posterior RARP and is a feasible surgical option for the treatment of prostate cancer.


Recruitment information / eligibility

Status Completed
Enrollment 233
Est. completion date December 27, 2022
Est. primary completion date May 31, 2022
Accepts healthy volunteers No
Gender Male
Age group N/A and older
Eligibility Inclusion Criteria: - pathologically diagnosed with prostate cancer by prostate biopsy - underwent robot-assisted laparoscopic surgery - the surgery performed by Weidong Gan - the extended pelvic lymphadenectomy (PLA) is performed on patients with high-risk prostate cancer (PSA=20 ng/ml or Grade Group 4-5 or clinical stage =T2c) and those considered to have a possibility of lymph node metastasis based on imaging evaluation. Exclusion Criteria: - Patients with a clinical and pathological TNM stage =T3b and N1 - patients with distant metastasis - urinary incontinence before surgery - received neoadjuvant therapy before surgery

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
the robot-assisted laparoscopic radical prostatectomy
We collect medical data of 233 patients with clinically localized prostate cancer who underwent AP-RARP, RS-RARP or anterior-RARP. Perioperative outcomes, including operation time, intraoperative blood loss, intraoperative and postoperative transfusion, postoperative infection, and anastomotic leakage, were compared among the three groups. The postoperative continence rates and PSM rates were also compared.

Locations

Country Name City State
China Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Nanjing University School of Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary urinary continence was defined as using 0-1 pad a day 0-6 month after surgery
Primary positive surgical margin observed whether the tissue cutting in surgery has tumor cell in surgical margin by pathologist 2 weeks after surgery
Secondary operating time The start time of the operation refers to the time of incision of the skin at the surgical site. The end time of surgery refers to the time when the skin is sutured. the day of the surgery
Secondary intraoperative blood loss Intraoperative bleeding was defined as the sum of blood content in blood gauze, blood content in negative pressure suction bottle and blood clot volume. the day of the surgery
See also
  Status Clinical Trial Phase
Recruiting NCT06315595 - Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion
Withdrawn NCT05191017 - Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC Phase 1/Phase 2
Completed NCT00255125 - Role of Soy Supplementation in Prostate Cancer Development Phase 3
Terminated NCT02809690 - 18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer Phase 1
Recruiting NCT03572946 - Targeted Biopsy or Standard Biopsy for Clinical Significant Prostate Cancer Detection N/A
Active, not recruiting NCT03344757 - Health Gatherings - For Your Health After Cancer N/A
Recruiting NCT05137561 - Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed TRUS Guided Prostate Biopsy N/A
Recruiting NCT04792138 - Learning MRI and Histology Image Mappings for Cancer Diagnosis and Prognosis.
Completed NCT03702439 - Prostate Cancer Screening Trial Using Imaging
Completed NCT04852224 - Strength, Aging, and Memory in Prostate Cancer
Completed NCT01240551 - F-18 Sodium Fluoride in Prostate Cancer Phase 2
Not yet recruiting NCT06430411 - Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
Recruiting NCT02436122 - Impact of Preoperative HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Prostate Cancer N/A
Active, not recruiting NCT03493945 - Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) Phase 1/Phase 2
Completed NCT04376008 - A Prospective Study Of Free-Hand Transperineal Image Fusion Targeted Biopsies Under Local Anesthesia N/A
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06292897 - Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression
Recruiting NCT03819751 - MRI-targeted Biopsy of the Prostate: Software Versus Visual Registration in the Accuracy of Prostate Cancer Detection N/A
Not yet recruiting NCT05460312 - Protein Kinase A in Prostate Cancer Tissue.
Completed NCT00005916 - PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer Phase 2